CD86 is an activation receptor for nk cell cytotoxicity against tumor cells

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Peng, Yanmeng ^a,b   Luo, Gaoxing ^a,b   Zhou, Junyi ^a,b   Wang, Xiaojuan ^a,b   Hu, Jie ^a,b   Cui, Yanyan ^a,b   Li, Xian C ^c   Tan, Jianglin ^a,b   Yang, Sisi ^a,b   Zhan, Rixing ^a,b   Yang, Junjie ^a,b   He, Weifeng ^a,b   Wu, Jun ^a,b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Chongqing Key Laboratory for Disease Proteomics   (China)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CD86 ANTIGEN; DACLIZUMAB; LYMPHOCYTE RECEPTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PERFORIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DEPLETION; LYMPHOID CELL LINE; MELANOMA B16; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; TUMOR CELL; TUMOR IMMUNITY; UPREGULATION;

ANIMALS; ANTIGENS, CD86; CELL LINE, TUMOR; HUMANS; IMMUNITY, CELLULAR; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MELANOMA; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL;

EID: 84892587077     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083913     Document Type: Article

References (23)

1. Gorczynski RM, Kiziroglu F (1994) Role of CTLA 4-Ig on induction of unresponsiveness to multiple minor alloantigens. Transpl Int 7 Suppl 1: S599-S601. doi:10.1111/j.1432-2277.1994.tb01453.x. PubMed: 11271318.
2. Finck BK, Linsley PS, Wofsy D (1994) Treatment of murine lupus with CTLA4Ig. Science 265: 1225-1227. doi:10.1126/science.7520604. PubMed: 7520604.
3. Webb LM, Walmsley MJ, Feldmann M (1996) Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 26: 2320-2328. doi:10.1002/eji.1830261008. PubMed: 8898940.
4. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N et al. (2005) Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5: 443-453. doi:10.1111/j.1600-6143.2005.00749.x. PubMed: 15707398.
5. Dumont FJ (2004) Technology evaluation: abatacept, Bristol-Myers Squibb. Curr Opin Mol Ther 6: 318-330. PubMed: 15264435.
6. Allison C (2005) Abatacept as add-on therapy for rheumatoid arthritis. Issues Emerg Health Technol: 1-4. PubMed: 16317826.
7. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J et al. (2005) Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52: 2263-2271. doi:10.1002/art.21201. PubMed: 16052582.
8. Hervey PS, Keam SJ (2006) Abatacept. BioDrugs 20: 53-61; discussion: 10.2165/00063030-200620010-00004. PubMed: 16573350.
9. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F et al. (2002) CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3: 1097-1101. doi:10.1038/ni846. PubMed: 12368911.
10. Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A et al. (2004) Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol 173: 3716-3724. PubMed: 15356117.
11. Hanna J, Fitchett J, Rowe T, Daniels M, Heller M et al. (2005) Proteomic analysis of human natural killer cells: insights on new potential NK immune functions. Mol Immunol 42: 425-431. doi:10.1016/j.molimm.2004.07.022. PubMed: 15607794.
12. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI et al. (2006) CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 176: 1582-1587. PubMed: 16424187.
13. Maxwell LJ, Singh JA (2010) Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 37: 234-245. doi:10.3899/jrheum.091066. PubMed: 20080922.
14. Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS et al. (2009) Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 36: 736-742. doi:10.3899/jrheum.080813. PubMed: 19273451.
15. Tremblay F, Fernandes M, Habbab F, Edwardes Deb, Loertscher R et al. (2002) Malignancy after renal transplantation: incidence and role of type of immunosuppression. Ann Surg Oncol 9: 785-788. doi:10.1007/BF02574501. PubMed: 12374662.
16. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G et al. (1998) Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 351: 623-628. doi:10.1016/S0140-6736(97)08496-1. PubMed: 9500317.
17. Walker LS, Sansom DM (2011) The emerging role of CTLA4 as a cellextrinsic regulator of T cell responses. Nat Rev Immunol 11: 852-863. doi:10.1038/nri3108. PubMed: 22116087.
18. Qureshi OS, Kaur S, Hou TZ, Jeffery LE, Poulter NS et al. (2012) Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation. J Biol Chem 287: 9429-9440. doi:10.1074/ jbc.M111.304329. PubMed: 22262842.
19. Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN (2002) Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 277: 7766-7775. doi:10.1074/jbc.M105902200. PubMed: 11726649.
20. Hunter CA, Ellis-Neyer L, Gabriel KE, Kennedy MK, Grabstein KH et al. (1997) The role of the CD28/B7 interaction in the regulation of NK cell responses during infection with Toxoplasma gondii. J Immunol 158: 2285-2293. PubMed: 9036976.
21. Wilson JL, Charo J, Martín-Fontecha A, Dellabona P, Casorati G et al. (1999) NK cell triggering by the human costimulatory molecules CD80 and CD86. J Immunol 163: 4207-4212. PubMed: 10510357.
22. Martín-Fontecha A, Assarsson E, Carbone E, Kärre K, Ljunggren HG (1999) Triggering of murine NK cells by CD40 and CD86 (B7-2). J Immunol 162: 5910-5916. PubMed: 10229827.
23. Trinchieri G, Valiante N (1993) Receptors for the Fc fragment of IgG on natural killer cells. Nat Immun 12: 218-234. PubMed: 8257828.